Tilray Inc (NASDAQ:TLRY - Get Free Report) traded down 5.1% on Friday . The company traded as low as $0.44 and last traded at $0.44. 5,821,883 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 34,593,969 shares. The stock had previously closed at $0.46.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. Roth Capital restated a "neutral" rating on shares of Tilray in a research note on Monday, April 14th. Piper Sandler dropped their price objective on Tilray from $2.00 to $1.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th.
Check Out Our Latest Stock Report on Tilray
Tilray Trading Down 5.7%
The firm has a 50 day moving average of $0.49 and a 200 day moving average of $0.89. The company has a quick ratio of 1.58, a current ratio of 2.54 and a debt-to-equity ratio of 0.10. The firm has a market cap of $441.05 million, a PE ratio of -1.46 and a beta of 1.95.
Tilray (NASDAQ:TLRY - Get Free Report) last issued its earnings results on Tuesday, April 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The business had revenue of $185.78 million for the quarter, compared to the consensus estimate of $213.38 million. Equities analysts anticipate that Tilray Inc will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Tilray
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Lido Advisors LLC bought a new position in shares of Tilray in the fourth quarter worth $28,000. Dudley Capital Management LLC bought a new position in shares of Tilray in the fourth quarter worth $29,000. Verdence Capital Advisors LLC bought a new position in shares of Tilray in the fourth quarter worth $29,000. Newman Dignan & Sheerar Inc. increased its holdings in shares of Tilray by 61.9% in the fourth quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company's stock worth $35,000 after purchasing an additional 10,000 shares during the period. Finally, Brooklyn FI LLC bought a new position in Tilray in the fourth quarter valued at $36,000. Institutional investors own 9.35% of the company's stock.
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
See Also
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
